2018-1205 NmeCas 9 is an intrinsically high-fidelity genome-editing platform

@inproceedings{Amrani201920181205N9,
  title={2018-1205 NmeCas 9 is an intrinsically high-fidelity genome-editing platform},
  author={Nadia Amrani and Xin D Gao and Pengpeng Liu and Alireza Edraki and Aamir Mir and Raed Ibraheim and Ankit Gupta and Kanae E. Sasaki and Tong Wu and Paul Daniel Donohoue and Alexander H. Settle and Alexandra M. Lied and Kyle Mcgovern and Chris K. Fuller and Peter Cameron and Thomas G Fazzio and Lihua Julie Zhu and Scot A. Wolfe and Erik J Sontheimer},
  year={2019}
}
Background: The development of CRISPR genome editing has transformed biomedical research. Most applications reported thus far rely upon the Cas9 protein from Streptococcus pyogenes SF370 (SpyCas9). With many RNA guides, wildtype SpyCas9 can induce significant levels of unintended mutations at near-cognate sites, necessitating substantial efforts toward the development of strategies to minimize off-target activity. Although the genome-editing potential of thousands of other Cas9 orthologs… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 99 REFERENCES

Diversity and evolution of class 2 CRISPR–Cas systems

  • Nature Reviews Microbiology
  • 2017
VIEW 17 EXCERPTS
HIGHLY INFLUENTIAL

Mapping the genomic landscape of CRISPR–Cas9 cleavage

  • Nature Methods
  • 2017
VIEW 28 EXCERPTS
HIGHLY INFLUENTIAL

The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

An updated evolutionary classification of CRISPR–Cas systems

  • Nature Reviews Microbiology
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…